7-chloro-11H-benzo[c]quinolizin-11-ium-6-one

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 7-chloro-11H-benzo[c]quinolizin-11-ium-6-one
• 化学式: C13H9ClNO+
• 分子量: 230.67
• InChiKey: RTLDJHACRZJMMP-UHFFFAOYSA-O

计算性质

• 辛醇/水分配系数(LogP)：
  4.4
• 重原子数：
  16
• 可旋转键数：
  0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  24.3
• 氢给体数：
  1
• 氢受体数：
  1

文献信息

• Use of aliginate oligomers and CFTR modulators in treatment of conditions associated with CFTR dysfunction
  申请人：AlgiPharma AS

  公开号：US10751363B2

  公开（公告）日：2020-08-25

  A method is for the treatment of a condition in a subject, which arises from or is associated with CFTR dysfunction. The method includes administering to the subject an effective amount of a CFTR modulator together with an effective amount of an alginate oligomer. The condition can be cystic fibrosis (CF), non-compound CFTR gene mutation heterozygosity, abnormal mucus clearance in the respiratory tract and/or breathing difficulties resulting from chronic particulate inhalation, COPD, chronic bronchitis, emphysema, bronchiectasis, asthma or chronic sinusitis, or a complication of any of these.

  一种用于治疗受试者因 CFTR 功能障碍引起或与之相关的疾病的方法。该方法包括向受试者施用有效量的 CFTR 调节剂和有效量的藻酸盐低聚物。病症可以是囊性纤维化（CF）、非复合 CFTR 基因突变杂合子、呼吸道粘液清除异常和/或慢性微粒吸入导致的呼吸困难、慢性阻塞性肺病、慢性支气管炎、肺气肿、支气管扩张、哮喘或慢性鼻窦炎，或上述任何病症的并发症。
• USE OF ALGINATE OLIGOMERS AND CFTR MODULATORS IN THE TREATMENT OF CONDITIONS ASSOCIATED WITH CFTR DYSFUNCTION
  申请人：ALGIPHARMA AS

  公开号：EP3273995A1

  公开（公告）日：2018-01-31
• COMBINED USE OF ALGINATE OLIGOMERS AND THE CFTR MODULATOR LUMACAFTOR IN THE TREATMENT OF CONDITIONS ASSOCIATED WITH CFTR DYSFUNCTION
  申请人：ALGIPHARMA AS

  公开号：EP3273995B1

  公开（公告）日：2021-07-14
• USE OF ALGINATE OLIGOMERS TO ENHANCE THE TRANSLOCATION OF MICRO/NANOPARTICLES ACROSS MUCUS LAYERS
  申请人：ALGIPHARMA AS

  公开号：EP3768323A1

  公开（公告）日：2021-01-27
• Use of Glucosidase Inhibitors for Therapy of Mucovisidosis
  申请人：Becq Frèdèric

  公开号：US20070213357A1

  公开（公告）日：2007-09-13

  The invention relates to the use of glycosidase inhibitors selected from compounds of general formula (1), wherein R 1 represents a CH 3 group, or CH 2 OH, R 2 represents H or an alkyl group having 1-5 carbon atoms, or R 1 and R 2 together form a group having formula (II), with carbon in position (a) and nitrogen of formula (I) mentioned above, for the preparation of a medicament used to treat mucoviscidosis.